Skip to main content
. Author manuscript; available in PMC: 2021 Dec 5.
Published in final edited form as: Lancet. 2020 Nov 13;396(10265):1807–1816. doi: 10.1016/S0140-6736(20)32338-2

Table 3:

Adverse events in the intention-to-treat population

ECMO-facilitated resuscitation (n=15)
Standard ACLS treatment (n=15)
Number of patients with data Patients Number of patients with data Patients

Number of adverse events
Total number of adverse events 15 166 15 47
Patients with more than one event 15 15 (100%) 15 2 (13%)
Unsuccessful resuscitation from refractory cardiac arrest
Death before admission 15 2 (13%) 15 13 (87%)
Circulatory events
Cardiogenic shock 13 12 (92%) 2 2 (100%)
Inotropes or vasopressors in ICU 13 11 (85%) 2 2 (100%)
CNS events
Cerebral oedema 13 3 (23%) 2 1 (50%)
CNS diffuse ischaemia 13 6 (46%) 2 1 (50%)
Seizure activity 13 0 2 0
Cardiopulmonary resuscitation trauma
Retrosternal or intrathoracic bleeding 13 4 (31%) 2 1 (50%)
Rib fractures 13 11 (85%) 2 2 (100%)
Gastrointestinal events
Acute liver failure or injury 13 9 (69%) 2 2 (100%)
Renal events
Acute kidney injury requiring continuous renal replacement therapy or dialysis 13 10 (77%) 2 1 (50%)
Respiratory events
Aspiration pneumonitis or pneumonia 13 12 (92%) 2 2 (100%)
Pulmonary oedema 13 5 (38%) 2 2 (100%)
Unanticipated device-related adverse events
None 13 NA 2 NA
Procedure-related events
Cracked tubing connector replaced 13 1 (8%) 2 NA
Access-site bleeding requiring transfusion of >3 units of PRBC 13 2 (15%) 2 NA
IVC trauma, retroperitoneal bleeding 13 1 (8%) 2 NA

Data are n (%), unless otherwise specified. ACLS=advanced cardiac life support. ECMO=extracorporeal membrane oxygenation. ICU=intensive care unit. NA=not applicable. PRBC=packed red blood cells. IVC=inferior vena cava.